Topically administered infliximab can work in ulcerative proctitis despite the ineffectiveness of intravenous induction therapy.
Tamás
T
Molnár
Klaudia
K
Farkas
Ferenc
F
Nagy
István
I
Németh
Tibor
T
Wittmann
D000285:Administration, Rectal; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003113:Colonoscopy / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D011350:Proctocolitis / Q000175:diagnosis* / Q000188:drug therapy*; D011351:Proctoscopy / Q000379:methods; D012074:Remission Induction; D019233:Retreatment; D018570:Risk Assessment; D012720:Severity of Illness Index; D017211:Treatment Failure; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab